Skip to main content

From the helm: Proteomics International (ASX:PIQ), Dr. Richard Lipscombe, Managing Director

Bell Direct
July 7, 2025

In this episode of From the helm, Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.

In this video, Dr. Lipscombe covers:
·      (0:47): An overview of PIQ and its FY26 goals
·      (1:38): The significance of three world-first blood tests
·      (5:26): The global addressable markets for these conditions
·      (6:25): Clinical trial progress and commercialisation roadmap
·      (8:14): How the diagnostic tests work and deliver value to patients
·      (9:16): Commercialisation strategy across key regions
·      (11:23): Additional assets in the PIQ pipeline
·      (12:36): What investors can expect over the next 12 months

Note: This interview was recorded on 3 July 2025.

Morning Bell 21 April

Sophia Mavridis
April 21, 2023

Morning Bell 20 April

Grady Wulff
April 20, 2023

Morning Bell 19 April

Grady Wulff
April 19, 2023

Morning Bell 18 April

Sophia Mavridis
April 18, 2023

Morning Bell 17 April

Grady Wulff
April 17, 2023

Weekly Wrap 14 April

Grady Wulff
April 14, 2023

Morning Bell 14 April

Sophia Mavridis
April 14, 2023

Morning Bell 13 April

Grady Wulff
April 13, 2023

Morning Bell 12 April

Grady Wulff
April 12, 2023

Morning Bell 11 April

Sophia Mavridis
April 11, 2023

Morning Bell 6 April

Sophia Mavridis
April 6, 2023

Morning Bell 5 April

Sophia Mavridis
April 5, 2023